Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Net Income (2020 - 2025)

Historic Net Income for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.9 million.

  • Rhythm Pharmaceuticals' Net Income fell 2122.55% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 2572.22%. This contributed to the annual value of -$260.6 million for FY2024, which is 4111.16% down from last year.
  • Rhythm Pharmaceuticals' Net Income amounted to -$52.9 million in Q3 2025, which was down 2122.55% from -$46.6 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Net Income ranged from a high of $43.8 million in Q1 2021 and a low of -$141.4 million during Q1 2024
  • Moreover, its 5-year median value for Net Income was -$44.2 million (2023), whereas its average is -$44.9 million.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Net Income surged by 22805.88% in 2021 and then crashed by 22007.09% in 2022.
  • Over the past 5 years, Rhythm Pharmaceuticals' Net Income (Quarter) stood at -$50.9 million in 2021, then rose by 16.44% to -$42.5 million in 2022, then increased by 2.02% to -$41.6 million in 2023, then fell by 3.98% to -$43.3 million in 2024, then decreased by 22.2% to -$52.9 million in 2025.
  • Its Net Income was -$52.9 million in Q3 2025, compared to -$46.6 million in Q2 2025 and -$49.5 million in Q1 2025.